RIDDLE-M-X FOR TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (PHASE II)
Risk and response adaptive trial evaluating the addition of Selinexor to standard of care therapy for transplant-eligible, newly diagnosed multiple myeloma
More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient reported outcome measures.
IBIS FOR FUNCTIONAL HIGH RISK MULTIPLE MYELOMA (PHASE II)
An immuno-therapeutic salvage strategy for 'functional' high-risk (FHR) multiple myeloma incorporating Iberdomide, Isatuximab and Dexamethasone.
PRO FOR PATIENTS RECEIVING DVD
Patient Reported Outcomes in patients receiving DVd for relapsed multiple myeloma.
FRAIL-M FOR TRANSPLANT INELIGIBLE MYELOMA (PHASE I/II)
Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) – the FRAIL-M study
BelaCarD FOR RELAPSED REFRACTORY MULTIPLE MYELOMA (PHASE I/II) **recruitment closed**
A phase I/II single arm study of combination belantamab mafodotin, carfilzomib and dexamethasone in patients with early relapsed multiple myeloma.
IRIL FOR TRANSPLANT INELIGIBLE MYELOMA (PHASE II) **recruitment closed**
A prospective Phase II study of Isatuximab Rescue for Inadequate response to Lenalidomide and Dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma (IRIL)
VCD-D FOR TRANSPLANT INELIGIBLE MYELOMA (Phase II) **recruitment closed**
A randomized phase 2 study of bortezomib, cyclophosphamide and dexamethasone induction (VCD) compared with VCD and daratumumab induction followed by daratumumab maintenance (VCDD) for the initial treatment of transplant ineligible patients with multiple myeloma
V-VCD FOR TRANSPLANT ELIGIBLE MYELOMA (PHASE II) **recruitment closed**
An exploratory study of Venetoclax in combination with Bortezomib-Cyclophosphamide-Dexamethasone (VCD) induction therapy in newly diagnosed transplant eligible (NDTE MM) multiple myeloma with proteomic correlative studies
KappaMab FOR RELAPSED REFRACTORY MULTIPLE MYELOMA (Phase IIb) **recruitment closed**
A Phase IIb, open label, sequential cohort study comparing KappaMab alone to KappaMab in combination with lenalidomide and low dose dexamethasone (MRd) in Relapsed Refractory Multiple Myeloma
ITD FOR RELAPSED REFRACTORY MULTIPLE MYELOMA (PHASE II) **recruitment closed**
A prospective, multi-centre, single arm, phase 2 assessment of the efficacy and safety of the combination of ixazomib, thalidomide and dexamethasone (ITD) for relapsed and/or refractory multiple myeloma after 1 to 3 prior lines of therapy.